Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB3538 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#MAB3538, RRID:AB_10550932
- Product name
- FLG monoclonal antibody, clone FLG01
- Antibody type
- Monoclonal
- Description
- Mouse monoclonal antibody raised against recombinant FLG.
- Isotype
- IgG
- Antibody clone number
- FLG01
- Storage
- Store at 4°C. Do not freeze.
Submitted references Identifying novel genes contributing to asthma pathogenesis.
Cytokeratin, filaggrin, and p63 expression in reepithelialization during human cutaneous wound healing.
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.
Holloway JW, Koppelman GH
Current opinion in allergy and clinical immunology 2007 Feb;7(1):69-74
Current opinion in allergy and clinical immunology 2007 Feb;7(1):69-74
Cytokeratin, filaggrin, and p63 expression in reepithelialization during human cutaneous wound healing.
Kurokawa I, Mizutani H, Kusumoto K, Nishijima S, Tsujita-Kyutoku M, Shikata N, Tsubura A
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2006 Jan-Feb;14(1):38-45
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2006 Jan-Feb;14(1):38-45
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH
Nature genetics 2006 Apr;38(4):441-6
Nature genetics 2006 Apr;38(4):441-6
No comments: Submit comment
No validations: Submit validation data